Intelligence Feed event · Policy · 2026-09-09

    CRISPR Casgevy sales rise 78% QoQ to $76M following FDA label expansion

    Question

    CRISPR Casgevy sales rise 78% QoQ to $76M following FDA label expansion

    Direct answer

    CRISPR Therapeutics demonstrated commercial traction with Casgevy, as Q2 sales expanded 78% sequentially to reach $76 million. The therapy's growth trajectory was supported by regulatory progress including FDA label expansion to pediatric patients aged 2 and older. The expansion enhances addressable patient volumes in blood disorder indications, providing direct commercial validation for partnered commercialization programs with Vertex Pharmaceuticals.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Casgevy sales rise 78% QoQ to $76M following FDA label expansion”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-casgevy-sales-rise-78-qoq-to-76m-following-fda-label-expansion-31a685

    POLICY
    CRISPR Casgevy sales rise 78% QoQ to $76M following FDA label expansion
    CRISPR Therapeutics demonstrated commercial traction with Casgevy, as Q2 sales expanded 78% sequentially to reach $76 million. The therapy's growth trajectory was supported by regulatory progress including FDA label expansion to pediatric patients aged 2 and older. The expansion enhances addressable patient volumes in blood disorder indications, providing direct commercial validation for partnered commercialization programs with Vertex Pharmaceuticals.
    CRSPVRTX
    Impact
    62
    SEP 9
    SIG
    85%
    CRSPVRTX
    CRISPR Casgevy sales rise 78% QoQ to $76M following FDA label expansion
    CRISPR Therapeutics demonstrated commercial traction with Casgevy, as Q2 sales expanded 78% sequentially to reach $76 million. The therapy's growth trajectory was supported by regulatory progress including FDA label expansion to pediatric patients aged 2 and older. The expansion enhances addressable patient volumes in blood disorder indications, providing direct commercial validation for partnered commercialization programs with Vertex Pharmaceuticals.
    → FDA pediatric label expansion broadens Casgevy addressable patient population, driving higher commercial royalty and revenue recognition for CRSP and VRTX.
    Impact
    CRISPR Therapeutics demonstrated commercial traction with Casgevy, as Q2 sales expanded 78% sequentially to reach $76 million. The therapy's growth trajectory was supported by regulatory progress including FDA label expansion to pediatric patients aged 2 and older. The expansion enhances addressable patient volumes in blood disorder indications, providing direct commercial validation for partnered commercialization programs with Vertex Pharmaceuticals.
    Affected
    CRSPVRTX
    Transmission
    FDA pediatric label expansion broadens Casgevy addressable patient population, driving higher commercial royalty and revenue recognition for CRSP and VRTX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPcommercial therapy revenue expansion and regulatory label broadeningUp1-4wCasgevy Q2 sales reached $76M (+78% QoQ) and FDA approved pediatric label expansion.
    VRTXcommercial co-development revenue sharing on CasgevyUp1-4wVertex Pharmaceuticals co-develops and commercializes Casgevy.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month